Product Name:3-Methyl-2-(methylthio)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidin-4(3H)-one

IUPAC Name:3-methyl-2-(methylsulfanyl)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydropyrimidin-4-one

CAS:1628606-29-0
Molecular Formula:C12H19BN2O3S
Purity:97%
Catalog Number:CM210800
Molecular Weight:282.17

Packing Unit Available Stock Price($) Quantity
CM210800-1g in stock ȤƚŸŪ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:1628606-29-0
Molecular Formula:C12H19BN2O3S
Melting Point:-
Smiles Code:O=C1C(B2OC(C)(C)C(C)(C)O2)=CN=C(SC)N1C
Density:
Catalog Number:CM210800
Molecular Weight:282.17
Boiling Point:
MDL No:
Storage:

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
Boronic Acids and Esters
Boronic acids and boronate esters are commonly used reagents in Suzuki–Miyaura coupling chemistry. Organoboron derivatives are common reagents for C–C bond formation, either through classical palladium-mediated transformations or through other newer coupling methods. Boronic esters and acids are potential intermediates in the manufacture of many active pharmaceutical ingredients (API).
Boronic Acid For Sale
Find trusted boronic acid for sale. Any requirements and problems can ask us at any time.

Column Infos

Vimseltinib
Vimseltinib (DCC-3014) is a potent and highly selective oral CSF1R kinase inhibitor that selectively and effectively inhibits CSF1R by utilizing the unique characteristics of the switch control region that regulates kinase conformational activation. The key phase 3 MOTION study conducted by vimseltinib in patients with giant cell tumor of the tendon sheath (TGCT) has shown positive results, and it is expected to submit a listing application to the FDA and the European Union next year.

Related Products